Document is current

Any future updates will be listed below

Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

Crossref DOI link: https://doi.org/10.1186/s12885-016-2358-2

Published Online: 2016-05-24

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark